Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. [electronic resource]
Producer: 20120716Description: 4391-4 p. digitalISSN:- 1528-0020
- Amyloid -- metabolism
- Amyloidosis -- drug therapy
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Boronic Acids -- administration & dosage
- Bortezomib
- Cohort Studies
- Cyclophosphamide -- administration & dosage
- Cytogenetic Analysis
- Dexamethasone -- administration & dosage
- Humans
- Kidney -- drug effects
- Pyrazines -- administration & dosage
- Remission Induction
- Retrospective Studies
- Survival Analysis
- Time Factors
No physical items for this record
Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.